obesity

This section The partnership content providedThe content in this section is provided by Globenewswire for the purposes of distributing press data on behalf of its customers. Postmedia did not review the content. by Globenewswire Bread…

Carolina Rhoda/iStock via Getty Images Eli Lilly (NYSE:LLYPopular obesity treatment Zepbound could face direct competition from Viking TherapeuticsNASDAQ:VKTX), with the latter expected to launch its flagship weight loss product VK2735…

New data shows significant loss of fat mass while maintaining lean mass NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. today announced... (NYSE: ALUR), a company dedicated to eliminating obesity, announced three scientific…

Weight loss translates into profits for investors. Just look at Eli Lilly And Novo Nordisk. Both stocks have risen dramatically thanks in large part to their obesity drugs, with Lilly's stock more than quadrupling and Novo's…

In 2022, more than 1 billion people in the world were living with obesity, according to a new study published in The Lancet. The study estimated the individual and combined prevalence of underweight and obesity, and their changes, from…

© Reuters. The logo of Amgen and a robot miniature are seen in this illustration taken, July 17, 2023. REUTERS/Dado Ruvic/Illustration/File Photo By Deena Beasley (Reuters) -Amgen on Tuesday said its adjusted fourth-quarter profit…

Lina Moiseienko/iStock Editorial via Getty Images The recent momentum in biotech deal-making, the rising interest in weight-loss drugs, and the popularity of artificial intelligence have all added significance to this year's J.P. Morgan…

© Reuters. FILE PHOTO: The Eli Lilly logo is seen on one of the company's offices in San Diego, California, US, September 17, 2020. REUTERS/Mike Blake/File Photo By Sribarna Roy (Reuters) - Eli Lilly and Associates said on Friday it…

© Reuters. FILE PHOTO: Flags are seen outside the headquarters of Novo Nordisk in Copenhagen, Denmark, February 5, 2020. REUTERS/Jakob Grunholt Pedersen/File Photo Written by Dina Beasley SAN DIEGO (Reuters) - Novo Nordisk said…